Altus Power Statistics
Total Valuation
PCRX has a market cap or net worth of $1.04 billion. The enterprise value is $1.25 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
Earnings Date | Aug 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.30 million shares outstanding. The number of shares has decreased by -15.61% in one year.
Current Share Class | 46.30M |
Shares Outstanding | 46.30M |
Shares Change (YoY) | -15.61% |
Shares Change (QoQ) | -2.29% |
Owned by Insiders (%) | 0.96% |
Owned by Institutions (%) | 112.33% |
Float | 45.83M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 7.12 |
PS Ratio | 1.47 |
Forward PS | 1.38 |
PB Ratio | 1.34 |
P/TBV Ratio | 3.38 |
P/FCF Ratio | 9.09 |
P/OCF Ratio | 7.91 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 8.22, with an EV/FCF ratio of 10.67.
EV / Earnings | n/a |
EV / Sales | 1.77 |
EV / EBITDA | 8.22 |
EV / EBIT | 20.16 |
EV / FCF | 10.67 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.83.
Current Ratio | 2.38 |
Quick Ratio | 1.79 |
Debt / Equity | 0.83 |
Debt / EBITDA | 3.61 |
Debt / FCF | 5.39 |
Interest Coverage | 3.32 |
Financial Efficiency
Return on equity (ROE) is -15.57% and return on invested capital (ROIC) is 2.66%.
Return on Equity (ROE) | -15.57% |
Return on Assets (ROA) | 2.43% |
Return on Invested Capital (ROIC) | 2.66% |
Return on Capital Employed (ROCE) | 5.06% |
Revenue Per Employee | $893,478 |
Profits Per Employee | -$161,342 |
Employee Count | 790 |
Asset Turnover | 0.44 |
Inventory Turnover | 1.84 |
Taxes
In the past 12 months, PCRX has paid $20.91 million in taxes.
Income Tax | 20.91M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.29% in the last 52 weeks. The beta is 0.48, so PCRX's price volatility has been lower than the market average.
Beta (5Y) | 0.48 |
52-Week Price Change | +12.29% |
50-Day Moving Average | 23.73 |
200-Day Moving Average | 22.59 |
Relative Strength Index (RSI) | 49.56 |
Average Volume (20 Days) | 640,076 |
Short Selling Information
The latest short interest is 5.46 million, so 11.79% of the outstanding shares have been sold short.
Short Interest | 5.46M |
Short Previous Month | 5.60M |
Short % of Shares Out | 11.79% |
Short % of Float | 11.92% |
Short Ratio (days to cover) | 10.63 |
Income Statement
In the last 12 months, PCRX had revenue of $705.85 million and -$127.46 million in losses. Loss per share was -$2.81.
Revenue | 705.85M |
Gross Profit | 474.08M |
Operating Income | 61.97M |
Pretax Income | 100.55M |
Net Income | -127.46M |
EBITDA | 151.96M |
EBIT | 61.97M |
Loss Per Share | -$2.81 |
Full Income Statement Balance Sheet
The company has $445.86 million in cash and $631.40 million in debt, giving a net cash position of -$185.54 million or -$4.01 per share.
Cash & Cash Equivalents | 445.86M |
Total Debt | 631.40M |
Net Cash | -185.54M |
Net Cash Per Share | -$4.01 |
Equity (Book Value) | 757.77M |
Book Value Per Share | 16.88 |
Working Capital | 432.45M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $134.52 million and capital expenditures -$17.46 million, giving a free cash flow of $117.07 million.
Operating Cash Flow | 134.52M |
Capital Expenditures | -17.46M |
Free Cash Flow | 117.07M |
FCF Per Share | $2.53 |
Full Cash Flow Statement Margins
Gross margin is 67.16%, with operating and profit margins of 8.78% and -18.06%.
Gross Margin | 67.16% |
Operating Margin | 8.78% |
Pretax Margin | -15.10% |
Profit Margin | -18.06% |
EBITDA Margin | 21.53% |
EBIT Margin | 8.78% |
FCF Margin | 16.59% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 15.61% |
Shareholder Yield | 15.61% |
Earnings Yield | -11.98% |
FCF Yield | 11.00% |
Dividend Details Analyst Forecast
The average price target for PCRX is $27.14, which is 21.16% higher than the current price. The consensus rating is "Buy".
Price Target | $27.14 |
Price Target Difference | 21.16% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | 7.39% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 6 |